Get the Stockscreener App
14.30
4.38%
0.60
After Hours:
14.31
0.010
+0.07%
Theravance Biopharma Inc stock is traded at $14.30, with a volume of 848.82K.
It is up +4.38% in the last 24 hours and up +19.97% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$13.70
Open:
$14
24h Volume:
848.82K
Relative Volume:
2.52
Market Cap:
$720.17M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-15.54
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
+2.51%
1M Performance:
+19.97%
6M Performance:
+51.48%
1Y Performance:
+76.33%
1-Day Range:
$13.87
$14.42
1-Week Range:
$13.47
$14.42
52-Week Range:
$7.88
$14.55
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
14.30 | 686.93M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Sector ETF performance correlation with Theravance Biopharma Inc.July 2025 Price Swings & Verified Entry Point Signals - Newser
Volume spikes in Theravance Biopharma Inc. stock – what they meanMarket Movers & Weekly Consistent Profit Watchlists - Newser
Is Theravance Biopharma Inc. building a consolidation baseWeekly Investment Report & Free Growth Oriented Trading Recommendations - Newser
Live market analysis of Theravance Biopharma Inc.Quarterly Trade Review & Consistent Income Trade Ideas - Newser
Is Theravance Biopharma Inc. reversing from oversold territory2025 Market Overview & Free Real-Time Volume Trigger Notifications - Newser
Backtesting results for Theravance Biopharma Inc. trading strategiesJuly 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Benzinga
Long term hold vs stop loss in Theravance Biopharma Inc.2025 Trading Recap & Real-Time Chart Breakout Alerts - Newser
Quantitative breakdown of Theravance Biopharma Inc. recent moveWeekly Profit Recap & Weekly Breakout Watchlists - Newser
Theravance Biopharma stock initiated with Buy rating at B.Riley on respiratory therapy growth - Investing.com Canada
Measuring Theravance Biopharma Inc.’s beta against major indicesMarket Volume Report & Safe Entry Point Alerts - Newser
Invesco Ltd. Has $201,000 Stake in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue? - sharewise.com
What is Zacks Research's Forecast for TBPH Q3 Earnings? - MarketBeat
Sentiment analysis tools applied to Theravance Biopharma Inc.Weekly Stock Recap & Weekly High Return Forecasts - Newser
Risk vs reward if holding onto Theravance Biopharma Inc.Quarterly Market Summary & Stepwise Swing Trade Plans - Newser
Technical signs of recovery in Theravance Biopharma Inc.Market Trend Report & Free Real-Time Volume Trigger Notifications - Newser
Does Theravance Biopharma Inc. qualify in momentum factor screening2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
PDT Partners LLC Increases Stake in Theravance Biopharma, Inc. $TBPH - MarketBeat
Multiple System Atrophy Clinical Trials Analysis, 2025 | MSA Companies Include Theravance Biopharma, H. Lundbeck A/S, Yoda Pharmaceuticals, Alterity Therapeutics, CORESTEM, Inc., ProMIS Neurosciences - Barchart.com
What are the future prospects of Theravance Biopharma Inc.Market Performance Recap & Verified High Yield Trade Plans - beatles.ru
How volatile is Theravance Biopharma Inc. stock2025 Short Interest & Weekly High Potential Stock Alerts - beatles.ru
Theravance Biopharma (NASDAQ:TBPH) Reaches New 1-Year HighHere's What Happened - MarketBeat
What moving averages say about Theravance Biopharma Inc.Portfolio Value Report & Expert Approved Momentum Ideas - Newser
Using economic indicators to assess Theravance Biopharma Inc. potentialJuly 2025 Movers & Weekly High Return Opportunities - Newser
Published on: 2025-09-06 04:15:45 - Newser
How high can Theravance Biopharma Inc. stock goForecast Cut & Weekly Setup with ROI Potential - Newser
How is Theravance Biopharma Inc. managing supply chain issuesJuly 2025 Reactions & Scalable Portfolio Growth Methods - خودرو بانک
Can momentum traders help lift Theravance Biopharma Inc.Weekly Profit Summary & Verified Entry Point Signals - Newser
Is Theravance Biopharma Inc. part of any major indexJuly 2025 Spike Watch & Daily Technical Stock Forecast Reports - خودرو بانک
Is Theravance Biopharma Inc. stock risky to hold nowJuly 2025 Setups & Stock Portfolio Risk Management - خودرو بانک
Is Theravance Biopharma Inc. stock influenced by commodity pricesWeekly Trend Recap & AI Enhanced Market Trend Forecasts - خودرو بانک
Using portfolio simulators with Theravance Biopharma Inc. included2025 Dividend Review & Technical Confirmation Trade Alerts - Newser
Published on: 2025-09-05 16:30:11 - خودرو بانک
Russell Investments Group Ltd. Acquires 26,069 Shares of Theravance Biopharma, Inc. $TBPH - MarketBeat
Is Theravance Biopharma Inc. trending in predictive chart modelsMarket Sentiment Report & Free Low Drawdown Momentum Trade Ideas - Newser
Best data tools to analyze Theravance Biopharma Inc. stockProfit Target & Weekly Momentum Stock Picks - Newser
Will Theravance Biopharma Inc. benefit from AI trendsEarnings Summary Report & Free High Accuracy Swing Entry Alerts - خودرو بانک
Vanguard Group Inc. Acquires 69,919 Shares of Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Eastern Progress
Trend Report: How volatile is Theravance Biopharma Inc. stock2025 Stock Rankings & Consistent Growth Equity Picks - خودرو بانک
Has Theravance Biopharma Inc. formed a bullish divergence2025 Bull vs Bear & Growth Focused Entry Point Reports - Newser
Predicting Theravance Biopharma Inc. trend using moving averages2025 Support & Resistance & Fast Gaining Stock Reports - Newser
Is Theravance Biopharma Inc. stock ready for a breakout2025 Dividend Review & Technical Buy Zone Confirmation - Newser
Tools to assess Theravance Biopharma Inc.’s risk profile2025 Bull vs Bear & Risk Adjusted Buy and Sell Alerts - Newser
Is Theravance Biopharma Inc. a momentum stock2025 Retail Activity & Capital Efficiency Focused Ideas - خودرو بانک
Will Theravance Biopharma Inc. benefit from rising consumer demand2025 Key Highlights & Growth Focused Entry Reports - خودرو بانک
Using data tools to time your Theravance Biopharma Inc. exitDollar Strength & High Return Stock Watch Alerts - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc.Portfolio Update Report & Growth Oriented Trading Recommendations - Newser
Can Theravance Biopharma Inc. be recession proofMarket Volume Summary & Technical Confirmation Alerts - خودرو بانک
Is Theravance Biopharma Inc. a speculative investmentWeekly Volume Report & Risk Controlled Daily Trade Plans - خودرو بانک
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):